MAP Pharmaceuticals Inc. (MAPP) announced after the bell Wednesday that its New Drug Application resubmission for LEVADEX orally inhaled migraine drug, for the potential acute treatment of migraine in adults, has been accepted for filing by the FDA.
MAP Pharmaceuticals has gapped open sharply higher Friday morning and is now up 2.17 at $14.99 on above average volume. The stock has jumped to over a 2-week high and has re-crossed its 200-day moving average.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.